Open AccessShould Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Author(s) -
William Yaxley,
Rhian McBean,
David Wong,
David Robert Grimes,
P. Vasey,
Mark Frydenberg,
John Yaxley
Publication year - 2021
Publication title -
investigative and clinical urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.653
H-Index - 14
eISSN - 2466-054X
pISSN - 2466-0493
DOI - 10.4111/icu.20210097
Subject(s) - medicine , prostate cancer , oncology , lymph node , urology , chemotherapy , prostate specific antigen , metastasis , cancer
Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is unknown. The aim was to assess the outcome of Lu-PSMA RLT earlier in the treatment of men with only LNM.